Development and validation of high performance liquid c

Journal of Pharmaceutics & Drug Delivery Research .ISSN: 2325-9604

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Development and validation of high performance liquid chromatography method for Atorvastatin calcium in pharmaceutical dosage forms

M Diril, G Yıldız Türkyılmaz and H Y Karasulu

Ege University, Turkey
: J Pharm Drug Deliv Res


Atorvastatin calcium (AtrCa) is a BCS class 2 classification group and displays low resolution with high permeability. AtrCa has almost 14% bioavability absolutely. The aim of this study is to develop and validate an analytical method for oral delivery of AtrCa in pharmaceutical dosage form. The HPLC system consisted of a gradient pump, thermo stable column department and a UV detector supplied by Agilent 1100. The column was a C18 column (5 μm, 150x4,6 mm) (ACE). All UV-Vis spectrums were monitored between 200-400 nm and quantification was performed at 238 nm. The injection volume was 20μL and the retention time of AtrCa was about 7.1 min. The mobile phase was mixture of acetonitrile and 0.1 M sodium di-hydrogen phosphate (55:45) (v/v) and adjusted to pH 3 with trifluoroacetic acid (1 mL) pumped at 1 mL/min. The HPLC method was validated partially with respect to linearity, limit of detection (LOD) and quantitation (LOQ), precision and accuracy. The linearity between peak area and concentration was analyzed using three calibration curves obtained in the different days with standard solutions of AtrCa at 11 different concentrations ranging from 0.065 to 20 ppm for AtrCa. Data indicate that AtrCa peak area is linear over concentration range of 0.065-20 ppm. The R2 for regression line is 0.999 with slope of 61.428 and y+ intercept of 15.33. LOD was found 0.429 μg /mL and LOQ was found 1.30 μg/mL. In conclusion, an efficient high performance liquid chromatographic method was developed and validated method described is suitable for oral delivery of AtrCa.



Track Your Manuscript